Adcentrx Therapeutics granted Fast Track Designation for ADRX-0706 nectin-4 ADC for the treatment of advanced cervical cancer

CAR-T Digest - August 2020

06 May 2025: Adcentrx Therapeutics granted Fast Track Designation for ADRX-0706 nectin-4 ADC for the treatment of advanced cervical cancer

Adcentrx Therapeutics received FDA Fast Track designation for its lead drug candidate, ADRX-0706, targeting locally advanced or metastatic squamous cell cervical cancer
ADRX-0706 is a nectin-4-directed antibody-drug conjugate currently being tested in a Phase 1a/b clinical trial, with interim data to be presented at the 2025 ASCO annual meeting
Early findings showed a favorable safety profile, including a lower incidence of peripheral neuropathy, and promising efficacy signals across multiple solid tumors
Nectin-4 is highly expressed in cervical cancer, making it a strong target for ADRX-0706 and addressing a major unmet need for patients with limited treatment options